JP2013521310A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013521310A5 JP2013521310A5 JP2012556265A JP2012556265A JP2013521310A5 JP 2013521310 A5 JP2013521310 A5 JP 2013521310A5 JP 2012556265 A JP2012556265 A JP 2012556265A JP 2012556265 A JP2012556265 A JP 2012556265A JP 2013521310 A5 JP2013521310 A5 JP 2013521310A5
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- subject
- plasma
- serum
- baseline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002966 serum Anatomy 0.000 claims 35
- 239000000203 mixture Substances 0.000 claims 28
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 claims 19
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims 19
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 19
- 229960002600 icosapent ethyl Drugs 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 17
- DSQFSRAJFCOGKA-GKFVBPDJSA-N (5z,8z,11z,14z)-2-ethylicosa-5,8,11,14-tetraenoic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCC(CC)C(O)=O DSQFSRAJFCOGKA-GKFVBPDJSA-N 0.000 claims 8
- 230000007423 decrease Effects 0.000 claims 8
- GIODNRPAARSHAH-UHFFFAOYSA-N ethyl octadeca-2,4,6,8-tetraenoate Chemical compound CCCCCCCCCC=CC=CC=CC=CC(=O)OCC GIODNRPAARSHAH-UHFFFAOYSA-N 0.000 claims 8
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 claims 6
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 3
- RRRQMBRDGQTXCC-UHFFFAOYSA-N ethyl nonadeca-2,4,6,8,10-pentaenoate Chemical compound CCCCCCCCC=CC=CC=CC=CC=CC(=O)OCC RRRQMBRDGQTXCC-UHFFFAOYSA-N 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 108010028554 LDL Cholesterol Proteins 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 229960001295 tocopherol Drugs 0.000 claims 2
- 229930003799 tocopherol Natural products 0.000 claims 2
- 235000010384 tocopherol Nutrition 0.000 claims 2
- 239000011732 tocopherol Substances 0.000 claims 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 2
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31044310P | 2010-03-04 | 2010-03-04 | |
| US61/310,443 | 2010-03-04 | ||
| PCT/US2011/027218 WO2011109724A1 (en) | 2010-03-04 | 2011-03-04 | Compositions and methods for treating and/or preventing cardiovascular disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016183057A Division JP2017025089A (ja) | 2010-03-04 | 2016-09-20 | 心血管疾患を処置及び／又は予防するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013521310A JP2013521310A (ja) | 2013-06-10 |
| JP2013521310A5 true JP2013521310A5 (enExample) | 2014-04-17 |
| JP6327497B2 JP6327497B2 (ja) | 2018-05-23 |
Family
ID=44531868
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012556265A Active JP6327497B2 (ja) | 2010-03-04 | 2011-03-04 | 心血管疾患を処置及び／又は予防するための組成物及び方法 |
| JP2016183057A Pending JP2017025089A (ja) | 2010-03-04 | 2016-09-20 | 心血管疾患を処置及び／又は予防するための組成物及び方法 |
| JP2018207855A Pending JP2019048843A (ja) | 2010-03-04 | 2018-11-05 | 心血管疾患を処置及び／又は予防するための組成物及び方法 |
| JP2020084402A Active JP7136526B2 (ja) | 2010-03-04 | 2020-05-13 | 心血管疾患を処置及び／又は予防するための組成物及び方法 |
| JP2020124388A Pending JP2020183428A (ja) | 2010-03-04 | 2020-07-21 | 心血管疾患を処置及び／又は予防するための組成物及び方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016183057A Pending JP2017025089A (ja) | 2010-03-04 | 2016-09-20 | 心血管疾患を処置及び／又は予防するための組成物及び方法 |
| JP2018207855A Pending JP2019048843A (ja) | 2010-03-04 | 2018-11-05 | 心血管疾患を処置及び／又は予防するための組成物及び方法 |
| JP2020084402A Active JP7136526B2 (ja) | 2010-03-04 | 2020-05-13 | 心血管疾患を処置及び／又は予防するための組成物及び方法 |
| JP2020124388A Pending JP2020183428A (ja) | 2010-03-04 | 2020-07-21 | 心血管疾患を処置及び／又は予防するための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (10) | US20110218243A1 (enExample) |
| EP (2) | EP3583849A1 (enExample) |
| JP (5) | JP6327497B2 (enExample) |
| KR (1) | KR20130026428A (enExample) |
| AU (1) | AU2011222544A1 (enExample) |
| BR (1) | BR112012022336A2 (enExample) |
| CA (4) | CA3043081C (enExample) |
| ES (1) | ES2750365T3 (enExample) |
| MX (1) | MX337315B (enExample) |
| PH (3) | PH12012501755A1 (enExample) |
| RU (3) | RU2728825C2 (enExample) |
| SG (1) | SG183883A1 (enExample) |
| WO (1) | WO2011109724A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4137128A1 (en) | 2008-09-02 | 2023-02-22 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same |
| MX350088B (es) | 2009-04-29 | 2017-08-25 | Amarin Pharma Inc | Composicion farmaceutica estable y metodos de uso de la misma. |
| NZ720946A (en) | 2009-04-29 | 2017-09-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| CN108096209A (zh) | 2009-06-15 | 2018-06-01 | 阿马里纳制药公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法 |
| US20110071176A1 (en) | 2009-09-23 | 2011-03-24 | Amarin Pharma, Inc. | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| PH12012501755A1 (en) * | 2010-03-04 | 2012-11-12 | Amarin Pharma Inc | Compositions and methods for treating and/or preventing cardiovascular disease |
| NZ712068A (en) | 2010-11-29 | 2017-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| ES2891473T3 (es) * | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
| WO2013192109A1 (en) * | 2012-06-17 | 2013-12-27 | Matinas Biopharma, Inc. | Omega-3 pentaenoic acid compositions and methods of use |
| US20150157593A1 (en) * | 2012-06-29 | 2015-06-11 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing ldl-p |
| BR112014032699A2 (pt) * | 2012-06-29 | 2017-06-27 | Amarin Pharmaceuticals Ie Ltd | métodos de tratamento de síndrome metabólica pediátrica |
| CA3067012C (en) | 2012-06-29 | 2021-10-05 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| EP2911657A4 (en) * | 2012-10-23 | 2016-08-03 | Univ Deakin | METHOD OF LOWERING TRIGLYCERIDES |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US10123986B2 (en) | 2012-12-24 | 2018-11-13 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
| US9629820B2 (en) | 2012-12-24 | 2017-04-25 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US20140221676A1 (en) * | 2013-02-06 | 2014-08-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating and/or preventing cardiovascular disease |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) * | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) * | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| WO2015066512A1 (en) * | 2013-10-31 | 2015-05-07 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| MA51766A (fr) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
| BR112022009189A2 (pt) | 2019-11-12 | 2022-07-26 | Amarin Pharmaceuticals Ie Ltd | Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial |
| US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| CN113346980B (zh) * | 2021-08-02 | 2023-08-11 | 浙江国利信安科技有限公司 | 用于消息转发的方法、电子设备和计算机存储介质 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4377526A (en) * | 1981-05-15 | 1983-03-22 | Nippon Suisan Kaisha, Ltd. | Method of purifying eicosapentaenoic acid and its esters |
| US4526902A (en) * | 1983-10-24 | 1985-07-02 | Century Laboratories, Inc. | Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions |
| US4920098A (en) * | 1986-09-17 | 1990-04-24 | Baxter International Inc. | Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases |
| US5252333A (en) * | 1987-04-27 | 1993-10-12 | Scotia Holdings Plc | Lithium salt-containing pharmaceutical compositions |
| US5198468A (en) * | 1987-06-24 | 1993-03-30 | Efamol Holdings Plc | Essential fatty acid composition |
| GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| IE63225B1 (en) * | 1988-09-13 | 1995-04-05 | Efamol Holdings | Use of fatty acids in the treatment of myalgic encephalomyelitis |
| US4935243A (en) * | 1988-12-19 | 1990-06-19 | Pharmacaps, Inc. | Chewable, edible soft gelatin capsule |
| JP2839276B2 (ja) * | 1989-01-23 | 1998-12-16 | 日本分光工業株式会社 | 超臨界流体抽出・分離方法及び装置 |
| US5457130A (en) * | 1989-03-20 | 1995-10-10 | Cancer Research Campaign Technology Limited | Eicosapentaenoic acid used to treat cachexia |
| GB9012651D0 (en) * | 1990-06-06 | 1990-07-25 | Efamol Holdings | Essential fatty acid treatment |
| US5215630A (en) * | 1991-06-04 | 1993-06-01 | Nippon Suisan Kaisha, Ltd. | Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation |
| DE4133694C2 (de) * | 1991-10-11 | 1993-10-07 | Fresenius Ag | Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen |
| JP3400466B2 (ja) * | 1991-10-28 | 2003-04-28 | 日本水産株式会社 | 高純度エイコサペンタエン酸またはそのエステルの製造方法 |
| JPH0649479A (ja) * | 1992-07-28 | 1994-02-22 | Maruha Corp | ω−３不飽和脂肪酸系化合物の安定化法 |
| GB9217780D0 (en) * | 1992-08-21 | 1992-10-07 | Efamol Holdings | Fatty acid treatment |
| US5888541A (en) * | 1992-08-21 | 1999-03-30 | Scotia Holdings Plc | Fatty acid treatment |
| GB9403857D0 (en) * | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
| US5760081A (en) * | 1994-05-10 | 1998-06-02 | The General Hospital Corporation | Omega 3 fatty acids in the prevention of ventricular fibrillation |
| AU711482B2 (en) * | 1994-06-28 | 1999-10-14 | Scotia Holdings Plc | Compositions for treatment of diabetic complications |
| IT1274734B (it) * | 1994-08-25 | 1997-07-24 | Prospa Bv | Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti |
| MY118354A (en) * | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
| JPH0959206A (ja) * | 1995-08-25 | 1997-03-04 | Nippon Oil & Fats Co Ltd | エイコサペンタエン酸およびエイコサペンタエン酸エステルの製造方法 |
| GB9519661D0 (en) * | 1995-09-27 | 1995-11-29 | Scotia Holdings Plc | Fatty acid treatment |
| US5861399A (en) * | 1996-07-17 | 1999-01-19 | Heart Care Partners | Methods and compositions for the rapid and enduring relief of inadequate myocardial function |
| US20020055539A1 (en) * | 1996-10-02 | 2002-05-09 | Bockow Barry I. | Compositions and methods for treating cardiovascular conditions |
| JP4151853B2 (ja) * | 1996-10-11 | 2008-09-17 | スカリスタ リミテッド | エイコサペンタエン酸および／またはステアリドン酸を含む治療用薬剤 |
| WO1999022719A1 (fr) * | 1997-10-30 | 1999-05-14 | Morishita Jintan Co., Ltd. | Preparation de capsule contenant un acide gras insature ou un derive de celui-ci, et procede de fabrication |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| US20030104048A1 (en) * | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
| US6193999B1 (en) * | 1999-03-01 | 2001-02-27 | Banner Pharmacaps, Inc. | Gum acacia substituted soft gelatin capsules |
| DK1072198T3 (da) * | 1999-07-28 | 2008-09-22 | Swiss Caps Rechte & Lizenzen | Præparat til anvendelse som medikament og/eller ernæringstilskud |
| WO2001015552A1 (en) * | 1999-08-30 | 2001-03-08 | Ocean Nutrition Canada Ltd. | A nutritional supplement for lowering serum triglyceride and cholesterol levels |
| JP4170542B2 (ja) * | 1999-11-18 | 2008-10-22 | 日油株式会社 | 高度不飽和脂肪酸誘導体の製造方法及び高純度エイコサペンタエン酸誘導体 |
| ITMI20010129A1 (it) * | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
| NZ529339A (en) * | 2001-05-30 | 2004-08-27 | Laxdale Ltd | Coenzyme Q and eicosapentaenoic acid (EPA) |
| ITMI20012384A1 (it) * | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
| US20030166614A1 (en) * | 2002-03-01 | 2003-09-04 | Harrison Stanley F. | Method for reducing cholesterol and triglycerides |
| WO2004017958A1 (ja) * | 2002-08-20 | 2004-03-04 | Nikken Chemicals Co., Ltd. | 軟カプセル剤 |
| CA2506611A1 (en) * | 2002-11-22 | 2004-06-10 | Nippon Suisan Kaisha Ltd. | External composition containing polyunsaturated fatty acid or its salt or ester |
| EP1711173A2 (en) * | 2003-12-31 | 2006-10-18 | Igennus Limited | Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof |
| EP1833313A2 (en) * | 2004-10-15 | 2007-09-19 | Corporation Limited Photonz | Compositions containing high omega-3 and low saturated fatty acid levels |
| US20070191467A1 (en) * | 2004-12-06 | 2007-08-16 | Reliant Pharmaceutical, Inc. | Statin and omega-3 fatty acids for lipid therapy |
| BRPI0518398A2 (pt) * | 2004-12-06 | 2008-11-18 | Reliant Pharmaceuticals Inc | Ácidos graxos âmega-3 e agente deslipidÊmico para terapia de lipÍdeos |
| US20060135610A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
| GB2421909A (en) * | 2004-12-23 | 2006-07-12 | Laxdale Ltd | Pharmaceutical compositions comprising EPA and methods of use |
| US20070104779A1 (en) * | 2005-11-07 | 2007-05-10 | Rongen Roelof M | Treatment with omega-3 fatty acids and products thereof |
| EP2364701A1 (en) * | 2005-12-20 | 2011-09-14 | Cenestra, Llc | Omega-3 fatty acid formulations |
| EP2526937A1 (en) * | 2006-02-07 | 2012-11-28 | Mochida Pharmaceutical Co., Ltd. | Composition for prevention of recurrence of stroke |
| EP2777701A1 (en) * | 2006-05-31 | 2014-09-17 | Mochida Pharmaceutical Co., Ltd. | Composition for preventing the occurrence of a cardiovascular event in multiple risk patient comprising the ethyl ester of all-cis-5,8,11,14,17-icosapentaenoic acid |
| NZ573719A (en) * | 2006-07-05 | 2011-08-26 | Photonz Corp Ltd | Production of ultrapure eicosapentaenoic acid and polar lipids from largely heterotrophic culture of nitzschia laevis |
| WO2008012329A2 (en) * | 2006-07-28 | 2008-01-31 | V. Mane Fils | Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component |
| US20080125490A1 (en) * | 2006-11-03 | 2008-05-29 | My Svensson | Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids |
| ES2768091T3 (es) * | 2009-02-10 | 2020-06-19 | Amarin Pharmaceuticals Ie Ltd | Uso del éster etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia |
| CN108096209A (zh) * | 2009-06-15 | 2018-06-01 | 阿马里纳制药公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法 |
| PH12012501755A1 (en) * | 2010-03-04 | 2012-11-12 | Amarin Pharma Inc | Compositions and methods for treating and/or preventing cardiovascular disease |
-
2011
- 2011-03-04 PH PH1/2012/501755A patent/PH12012501755A1/en unknown
- 2011-03-04 EP EP19190599.1A patent/EP3583849A1/en not_active Withdrawn
- 2011-03-04 CA CA3043081A patent/CA3043081C/en active Active
- 2011-03-04 MX MX2012010253A patent/MX337315B/es active IP Right Grant
- 2011-03-04 BR BR112012022336-4A patent/BR112012022336A2/pt not_active Application Discontinuation
- 2011-03-04 RU RU2016129266A patent/RU2728825C2/ru active
- 2011-03-04 CA CA2792090A patent/CA2792090C/en active Active
- 2011-03-04 US US13/040,977 patent/US20110218243A1/en not_active Abandoned
- 2011-03-04 CA CA3147657A patent/CA3147657C/en active Active
- 2011-03-04 CA CA3066588A patent/CA3066588C/en active Active
- 2011-03-04 ES ES11751431T patent/ES2750365T3/es active Active
- 2011-03-04 JP JP2012556265A patent/JP6327497B2/ja active Active
- 2011-03-04 SG SG2012065215A patent/SG183883A1/en unknown
- 2011-03-04 EP EP11751431.5A patent/EP2542060B1/en active Active
- 2011-03-04 KR KR1020127024878A patent/KR20130026428A/ko not_active Ceased
- 2011-03-04 RU RU2012142181A patent/RU2606853C2/ru active
- 2011-03-04 AU AU2011222544A patent/AU2011222544A1/en not_active Abandoned
- 2011-03-04 WO PCT/US2011/027218 patent/WO2011109724A1/en not_active Ceased
-
2013
- 2013-08-28 US US14/012,625 patent/US20140128464A1/en not_active Abandoned
-
2015
- 2015-05-28 US US14/723,799 patent/US20150335607A1/en not_active Abandoned
-
2016
- 2016-09-20 JP JP2016183057A patent/JP2017025089A/ja active Pending
-
2017
- 2017-01-23 US US15/413,093 patent/US20170128406A1/en not_active Abandoned
-
2018
- 2018-04-19 PH PH12018500843A patent/PH12018500843B1/en unknown
- 2018-11-05 JP JP2018207855A patent/JP2019048843A/ja active Pending
-
2019
- 2019-05-06 US US16/404,558 patent/US20200297681A1/en not_active Abandoned
-
2020
- 2020-05-13 JP JP2020084402A patent/JP7136526B2/ja active Active
- 2020-07-08 US US16/923,311 patent/US20200360330A1/en not_active Abandoned
- 2020-07-17 RU RU2020123679A patent/RU2020123679A/ru unknown
- 2020-07-21 JP JP2020124388A patent/JP2020183428A/ja active Pending
-
2021
- 2021-01-19 US US17/151,956 patent/US20210260016A1/en not_active Abandoned
- 2021-01-21 US US17/154,357 patent/US20210386701A1/en not_active Abandoned
- 2021-04-06 PH PH12021550756A patent/PH12021550756A1/en unknown
- 2021-12-03 US US17/457,579 patent/US20220323393A1/en not_active Abandoned
-
2024
- 2024-03-13 US US18/603,789 patent/US20240216322A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012142181A (ru) | Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания | |
| JP2019048843A5 (enExample) | ||
| US20220347147A1 (en) | Compositions comprising 15-ohepa and methods of using the same | |
| NZ743706A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| JP2015143248A5 (enExample) | ||
| JP2020128412A5 (enExample) | ||
| NZ597193A (en) | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy | |
| US20020169209A1 (en) | Potentiation of therapeutic effects of fatty acids | |
| JP2015503593A5 (enExample) | ||
| JP2015503590A5 (enExample) | ||
| JP2008540394A5 (enExample) | ||
| CN1756545A (zh) | ω－3－脂肪酸在治疗糖尿病患者中的应用 | |
| SG10201400685SA (en) | Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia | |
| JP2004517148A (ja) | 心機能不全および心不全の治療における必須ｎ−３脂肪酸 | |
| RU2017112149A (ru) | Комбинация омега-3 жирной кислоты и SGLT-2 ингибитора для лечения болезней печени | |
| US12017986B2 (en) | Compositions comprising oxo-derivatives of fatty acids and methods of making and using same | |
| JP2016501248A5 (enExample) | ||
| JP2012506429A5 (enExample) | ||
| EA201100143A1 (ru) | Длительное лечение клинически выраженной сердечной недостаточности | |
| CN104382914B (zh) | 磷酸肌酸二钠盐在制备稳定和消退动脉粥样硬化斑块药物中的应用 | |
| CN110478338A (zh) | 丁内酯代谢酮i在降低血脂中的应用 | |
| Eriksdotter et al. | P1-384 EFFECTS OF OMEGA-3 FATTY ACID SUPPLEMENTATION ON PLASMA FATTY ACIDS, GENDER EFFECTS, AND EFFECTS ON COGNITION IN ALZHEIMER’S PATIENTS: THE OMEGAD STUDY | |
| Canamares-Orbis | Congestive heart failure: case report | |
| NZ807894B2 (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |